Get started
Work

Supplementary Figure 2 from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma

Year: 2023
Type: supplementary-materials
Abstract: PDF file - 5171K, Schematic representation of gain or deletions across the set of genes on each chromosome in a tumor with MITF amplification. Each dot corresponds to an exon of a specific gene. Every gene expressed higher than 1.5 is considered amplified, while every gene expressed lower than 0.5 is considered deleted. Exons corresponding to MITF are circled in red.
DOI: 10.1158/1078-0432.22451655.v1
Authors: Federica Catalanotti, David B. Solit, Melissa P. Pulitzer, Michael F. Berger, Sasinya N. Scott, Tunc Iyriboz, Mario E. Lacouture, Katherine S. Panageas, Jedd D. Wolchok, Richard D. Carvajal, Gary K. Schwartz, Neal Rosen, Paul B. Chapman
Language: English
Open Access status: gold
OpenAlex ID: W4361968168
Cites:
Cited by:
Related to: 10